Vaccine Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Bioterrorism
Aethlon Medical to Pursue U.S. Government Biodefense Contract
May 7th, 2008
Aethlon Medical, Inc. (OTCBB:AEMD) announced that it will submit a contract response to a BROAD AGENCY ANNOUNCEMENT (BAA) solicitation entitled "Application of Platform Technologies for the Development of Therapeutic Agents for Biodefense". This solicitation (DMID-NIAID-NIHAI20080022BARDA) represents a partnership between the National Institute of Allergy and Infectious Diseases (NIAID) and the recently established Biomedical Advanced Research and Development Authority (BARDA) to award contracts that fund the development and evaluation of innovative approaches to treat NIAID category A, B and C bioterror threats. Contract recipients will be awarded up to five years of funding directed...
Source: Vaccine Weekly (2008-05-07)
|
